CA-ATOMWISE
18.12.2020 12:02:07 CET | Business Wire | Press release
Atomwise , the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx , a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/
As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects. Atomwise and FutuRx have announced their first joint venture, A2i Therapeutics, with seed funding to leverage Atomwise’s AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target. Atomwise’s AI platform, AtomNet®, can screen more than 16 billion compounds for potential hits in less than two days and has been used by researchers around the world to find hits on targets across numerous disease applications.
“FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery,” said Kinneret Savitzky, PhD, Chief Executive Officer of FutuRx. “Atomwise brings a legacy of collaboration and innovation in small-molecule drug discovery to our network of leading experts from multinational pharmaceutical companies and venture capital, “We are happy that our partnership with Atomwise will introduce its innovative AI platform for drug discovery to startups and emerging biotech companies in Israel.”
“The Israeli Innovation Authority leads Israel’s Bio-convergence strategy and is happy to have FutuRx once again join this effort together with its new partner Atomwise,” said Anya Eldan, VP of the Innovation Authority and Head of Startup Division. “Atomwise is at the forefront of AI-driven drug discovery, and this partnership with FutuRx will help pursue difficult disease targets and significantly boost the Israeli AI drug discovery and bio-convergence ecosystem.”
FutuRx now joins Atomwise’s growing network of investor and corporate partnerships, which today represents a collective deal value approaching $7 billion. Since its founding, Atomwise has built a strong portfolio of joint-venture companies and partnerships with emerging biotechnology, leading pharmaceutical and agrochemical companies.
In April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma , a leading biopharmaceutical company in China, after successfully completing their first hit-discovery collaboration to identify hit compounds that are specific towards an intractable drug target. This announcement came on the heels of another expanded partnership earlier this year with Bayer to continue the development of two crop protection programs. As part of the strategic partnership, Atomwise is helping Bayer increase the speed and probability of discovering and developing new crop protection products through AI.
“We are excited to see Atomwise, a Leaps by Bayer portfolio company, collaborating with FutuRx on new frontiers for addressing our shared goal of curing and preventing cancer,” said Dr. Juergen Eckhardt, Head of Leaps by Bayer.
About FutuRx
FutuRx is the leading biotechnology incubator in Israel, established in 2014 by Johnson & Johnson Innovation (JJDC, Inc.), OrbiMed Israel Partners, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc., after winning a tender of the Israeli Innovation Authority. Recently Bayer has joined FutuRx as a strategic investor through its corporate venture LEAPS. The incubator is focused on innovative, early stage therapeutic technologies, and has established 23 companies to date. For more information about FutuRx, please visit https://www.futurx.co.il .
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 15:00:00 CEST | Press release
Wasabi remains official cloud storage partner of Liverpool FC during its worldwide expansion, helping fuel the Club’s global digital content strategy Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom